OTC Cholesterol Drugs May Be Revisited By FDA In 2000
This article was originally published in The Tan Sheet
Executive Summary
FDA will re-examine the question of potential Rx-to-OTC switches of hypercholesterolemia drugs in 2000, including reexamination of a 1997 guidance finding such drugs inappropriate for over-the-counter sale, Center for Drug Evaluation & Research Director Janet Woodcock, MD, said Dec. 16.
You may also be interested in...
Cholesterol Rx Drugs Reported Topic Of July NDAC Meeting
FDA may be moving toward softening its firm stance, announced in a 1997 guidance, against over-the-counter use of cholesterol-lowering drugs.
Rx-To-OTC Switches "Not In Financial Interests" Of Manufacturers - Juhl
Three years of market exclusivity following an Rx-to-OTC switch might not be enough of an incentive to encourage manufacturers to apply for switches, former FDA Nonprescription Drugs Advisory Committee chair Randy Juhl, PhD, University of Pittsburgh, suggested at the American Pharmaceutical Association annual meeting March 11.
Warner-Lambert/Pfizer Consumer Healthcare Sales Top $3.5 Bil.
The combination of Warner-Lambert and Pfizer will create a firm with consumer healthcare sales of over $3.5 bil., based on 1999 results, with W-L contributing roughly $3 bil. of the total.